PTC THERAPEUTICS, INC.
StreetZero Signal 49
About PTC THERAPEUTICS, INC.
PTC Therapeutics, Inc. is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. The company is advancing a robust and diversified pipeline of transformative medicines to provide access to best-in-class treatments for patients with unmet medical needs. PTC Therapeutics (NASDAQ: PTCT) is a science-driven company focused on medicines that provide benefits to patients with rare disorders.
LATEST FUNDINGRule 144
$12K
Announced 2026-10-09
TOTAL RAISED$248M
IN THE NEWS
- 🔗 PTC Therapeutics grants 300 RSUs in Nasdaq inducement award | PTCT Stock News
- 🔗 PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding | PTC Therapeutics.
- 🔗 PTC Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
- 🔗 SEC Filing | PTC Therapeutics.
EMPLOYEES991
FOUNDED—
HQWarren, NJ, USA
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalRare DiseasesPublicNASDAQ:PTCT
Investors
Key highlights
- Announced strategic financing collaboration with Blackstone for up to $1B in October 2022.
- Total funding raised stands at $248M across 24 rounds.
- Focuses on medicines for rare disorders including Duchenne muscular dystrophy and AADC deficiency.
- Reported Q3 sales of $217.13 million beating consensus estimates.
Ask StreetZero about PTC THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account